Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free...
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
About this item
Full title
Author / Creator
Klemen, Nicholas D. , Wang, Melinda , Feingold, Paul L. , Cooper, Kirsten , Pavri, Sabrina N. , Han, Dale , Detterbeck, Frank C. , Boffa, Daniel J. , Khan, Sajid A. , Olino, Kelly , Clune, James , Ariyan, Stephan , Salem, Ronald R. , Weiss, Sarah A. , Kluger, Harriet M. , Sznol, Mario and Cha, Charles
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or stereotactic body radiotherapy (SBRT) may be useful to manage limited progression, but criteria for patient selection have not been established....
Alternative Titles
Full title
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c07c26e6a44a4ce78d04b751b2c59125
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c07c26e6a44a4ce78d04b751b2c59125
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1186/s40425-019-0672-3
